About DNage
DNage is a Healthcare company based in Leiden (Netherlands) founded in 2004 by Jan Hoeijmakers, Wim Vermeulen, Roland Kanaar, and Gijsbertus Van Der Horst, and was acquired by Pharming Group in October 2006. Therapies for DNA damage-related ageing diseases are developed. DNage has raised $1.94 million across 1 funding round from investors including Pharming Group, Life Sciences Partners and Inventages. DNage offers products and services including Dietary Supplement. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders. Its legal entity is DNage Products N.V. Its competitors include Pharvaris and ProQR Therapeutics; 2 of its 2 listed competitors have raised funding.
Company details
DNage was founded in 2004 as a spin-off from the Department of Genetics at Erasmus Medical Center Rotterdam and is located in Leiden, Netherlands. Therapies targeting ageing diseases caused by DNA damage are developed, with programs in neurodegeneration, bone disease, and related pathologies. The lead product, Prodarsana small molecule combination for Cockayne Syndromewas approved by the FDA in August 2009, after acquisition by Pharming Group in 2006.
- Headquarters Leiden, Netherlands
- Founders Jan Hoeijmakers, Wim Vermeulen, Roland Kanaar, Gijsbertus Van Der Horst
- Stage Acquired
- SectorsHealthcare
- Website dnage.nl
- Social LinkedIn X
- Acquired by Pharming Group (Oct 2006)
- Legal Name Dnage Products N.V.
- Total Equity Funding$1.94M (USD)
in 1 rounds
- Latest Funding Round$1.94M (USD), Series A
Apr 2005
- InvestorsPharming Group
& 2 more
- Acquired byPharming Group
(Oct 2006)
Products & Services of DNage
DNage offers a comprehensive portfolio of products and services, including Dietary Supplement.
Supplement for DNA damage repair to support anti-ageing and health benefits.
Funding Insights of DNage
DNage has successfully raised a total of $1.94M through 1 strategic funding round. The most recent funding activity was a Series A round of $1.94 million completed in April 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.94M
- Total Rounds 1
- Last Round Series A — $1.94M
- First Round $1.94M
(Apr 2005)
- Investors Count 2
All 1 funding rounds of DNage with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2005 | $1.94M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in DNage
DNage has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Pharming Group, Life Sciences Partners and Inventages.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
| inventages.com | ||||
Recombinant protein-based therapeutics for rare diseases are developed. | 1988 | pharming.com | Leiden, Netherlands |
Investor details for DNage
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of DNage
4 people are tracked at DNage (4 in leadership).
| Name | Role | Group |
|---|---|---|
Jan Hoeijmakers | Co-Founder | Leadership |
Wim Vermeulen | Co-Founder | Leadership |
Roland Kanaar | Co-Founder | Leadership |
Gijsbertus Van Der Horst | Co-Founder | Leadership |
Complete people profiles for DNage
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of DNage
3 dated milestones of DNage across 2 years, from founding to its latest funding, stage changes and deals.
- Founded DNage is founded.
- Funding First funding round of $1.9M.
- Exit Acquired by Pharming Group.
Competitors of DNage
DNage has 2 listed competitors in our database, 2 of them funded. They include Pharvaris and ProQR Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pharvaris.com | 2015 | Leiden, Netherlands | $164.21M | Orally deliverable bradykinin B2 antagonists are developed for hereditary angioedema. | ||
| proqr.com | 2012 | Leiden, Netherlands | $57.99M | RNA-based therapeutics are developed for genetic retinal disorders. |
Detailed competitors of DNage
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about DNage
DNage was founded in 2004 and raised its 1st funding round 1 year after it was founded.
DNage is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
DNage is a funded company, having raised a total of $1.94M across 1 funding round to date. The company's 1st funding round was a Series A of $1.94M, raised on Apr 2005.
DNage was founded in 2004 as a spin-off from the Department of Genetics at Erasmus Medical Center Rotterdam and is located in Leiden, Netherlands. Therapies targeting ageing diseases caused by DNA damage are developed, with programs in neurodegeneration, bone disease, and related pathologies. The lead product, Prodarsana small molecule combination for Cockayne Syndromewas approved by the FDA in August 2009, after acquisition by Pharming Group in 2006.
DNage's top competitors include Pharvaris and ProQR Therapeutics.
DNage offers Dietary Supplement.
DNage has 3 investors. Key investors include Pharming Group, Life Sciences Partners, and Inventages.
DNage operates through Dnage Products N.V..
Yes. DNage was acquired by Pharming Group in October 2006.